Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors
Clinical trial NCT04034238 · COMPLETED
Trial details
- NCT number
- NCT04034238
- Sponsor
- National Cancer Institute (NCI)
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2019-08-29
- Primary completion
- 2020-12-01
- Enrollment
- 19
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.